The child's sex depends on the father's sex chromosomes. The Y chromosome carried by the father results in a male child, while the X chromosome results in a female child.
Chromosome tests evaluate chromosome number, structure, sex determination, genetic disease diagnosis and carrier screening, helping diagnose conditions such as Down, Klinefelter and Turner syndromes.
NIPT is a low-risk screening test that helps with early diagnosis, identifies genetic risks, allows psychological preparation, and supports decision-making during pregnancy.
The non-invasive prenatal test (NIPT) screens for chromosomal disorders such as Down, Edwards and Patau syndromes from a maternal blood sample, with no risk to mother or baby.
NIPT has high sensitivity and specificity, but it is a screening test, not a diagnostic test. Confirmation through invasive testing may be required for high-risk results.
During pregnancy, the baby's sex is usually determined between weeks 16 and 20 via ultrasound. Earlier blood tests and genetic tests are also available.
NIPT analyzes the baby's DNA from a blood sample taken from the mother's arm to detect chromosomal disorders, with results available in 3 to 5 working days.
Genoks was founded in 2008 by lawyer Özden BOSTAN. It is a pioneer in Turkey in NIPT performed with Next-Generation Sequencing (NGS) technology and operates as a Genetic Diseases Evaluation Center.